Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
Proteostasis Therapeutics (PTI) Surges 50% on FDA Breakthrough Therapy Designation for PTI-428
March 13, 2018 9:05 AM EDTProteostasis Therapeutics (NASDAQ: PTI) surges 50% in pre-open trading after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for PTI-428, the Companys cystic fibrosis transmembrane conductance regulator (CFTR) amplifier.
... MoreProteostasis Therapeutics (PTI): Incrementally Positive on FDA Breakthrough Designation - Baird
March 13, 2018 6:44 AM EDTBaird analyst Brian Skorney is incrementally positive on Proteostasis Therapeutics' (NASDAQ: PTI) FDA breakthrough designation for PTI-428.
Skorney said the FDA designation should provide additional validation that the results demonstrated are clinically meaningful.
"We believe shares could be up significantly given... More
